PHILADELPHIA New randomized trial results show early aortic valve replacement (AVR) resulted in a lower risk for operative mortality or death from cardiovascular causes compared with conservative care in asymptomatic patients with severe aortic valve stenosis.
Secondary analysis also showed a reduced risk for all-cause mortality, the researchers report.
The results, from the Randomized Comparison of Early Surgery versus Conventional Treatment in Very Severe Aortic Stenosis (RECOVERY) trial, were presented here at the American Heart Association (AHA) Scientific Sessions 2019 and were published online November 16 in the New England Journal of Medicine.
"Early surgical aortic valve replacement, as compared with conventional treatment, significantly reduced the risk of operative or cardiovascular mortality and death from any cause among asymptomatic patients with very severe aortic stenosis," Duk-Hyun Kang, MD, PhD, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea, told theheart.org | Medscape Cardiology.
"Our RECOVERY trial provides the evidence to support preemptive aortic valve replacement for asymptomatic severe aortic stenosis," he said.
Observers here, however, raised questions about the generalizability of these results, since the patients in the trial were relatively young, there was a high incidence of bicuspid aortic valve disease, there were few comorbidities, and operative risk was low, something the researchers also point out in their article.
"Thus, our trial population is quite different from the populations enrolled in TAVR [transcatheter aortic valve replacement] trials, and the results of our trial cannot be directly applied to early TAVR for asymptomatic severe aortic stenosis," the researchers conclude. Similarly, the results may not apply to lower-volume centers or to patients at higher operative risk.
AVR is the only effective therapy for severe aortic stenosis that is symptomatic, the authors write, and "despite limited data from randomized clinical trials, current guidelines recommend aortic-valve replacement because of the dismal nature of this disorder."
For the one third to one half of patients who are asymptomatic at diagnosis, though, the appropriate timing for intervention "remains controversial," they note.
"Based on the consensus opinion that the potential benefit of AVR to prevent sudden death may not be greater than the risk of AVR, watchful waiting is recommended for the vast majority of asymptomatic patients with severe aortic stenosis, with AVR planned once symptoms develop," Kang said.
Recent observational studies have suggested that early surgery is potentially beneficial in comparison with conventional treatment, he said, but these results might have been affected by baseline differences between treatment groups, treatment selection bias, or other unmeasured confounders.
"Only a randomized trial can reduce these limitations inherent to observational studies, and we conducted the first randomized trial to address the question of whether early AVR is preferable to a strategy in which AVR is deferred until symptoms develop," Kang said.
The RECOVERY trial aimed to compare long-term clinical outcomes of early surgical AVR with a conservative care strategy based on current guidelines in asymptomatic patients with severe aortic stenosis, defined as an aortic valve area of 0.75 cm2 with either an aortic jet velocity of 4.5 m/sec or a mean transthoracic gradient of 55 mmHg.
The primary endpoint was a composite of death during or within 30 days after surgery (operative mortality) or death from cardiovascular causes during follow-up. A major secondary endpoint was death from any cause. The mean peak aortic jet velocity was 5.1 0.5 m/sec, and the mean aortic valve area was 0.63 0.09 cm2.
Treatment groups were well balanced. The mean age of the patients was 64.2 9.4 years, and 49% were men. The cause of aortic stenosis was bicuspid aortic valve in 88 patients (61%), degenerative aortic valvular disease in 48 patients (33%), and rheumatic valvular disease in nine patients (6%).
Of the 73 patients assigned to early surgery, 69 underwent surgery (95%) within about 2 months after randomization. There was no operative mortality, Kang reported. "The median follow-up of our trial was 6.3 years, and no patients were lost to follow-up."
In the intention-to-treat analysis, which included all patients, one patient in the early surgery group and 11 patients in the conventional treatment group died from cardiovascular causes, he said. "The hazard ratio was 0.09, the number needed to treat to prevent one cardiovascular death within 4 years was 20 patients," he noted.
For the secondary endpoint of death from any cause, there were five such deaths in the early surgery group and 15 in the conventional treatment group. "The hazard ratio was 0.33, and the number needed to treat to save one life within 4 years was 16 patients," Kang said.
Table. RECOVERY: Primary and Secondary Outcomes by Intervention
The cumulative incidence of the primary endpoint, operative mortality or cardiovascular death, calculated by Kaplan-Meier analysis, was 1% at both 4 and 8 years in the early surgery group, vs 6% at 4 years, and 25.5% at 8 years in the conventional treatment group (P = .003).
The cumulative incidence of death from any cause was also lower in the early surgery group than in the conventional treatment group: 4% vs 10% at 4 years in the early surgery group vs conventional care, and 10% vs 32% at 8 years, Kang said.
Athena Poppas, MD, vice president of the American College of Cardiology (ACC) and professor of medicine at the Warren Alpert Medical School, Brown University, in Providence, Rhode Island, called the findings "very interesting and provocative, in that they had a high rate in the conservative group of sudden death, and that's certainly alarming. And these were clearly severe aortic stenosis by echo and not low-flow, low-gradient AS, which is another category."
In an older population, the surgical mortality would be higher and the morbidity would be higher, Poppas told theheart.org | Medscape Cardiology, "and so I don't think we can apply those findings to that group."
But the findings could be applied, for example, to the bicuspid valve group, for whom operative mortality should be very low, she said. "They had no operative deaths sort of confirming that it was a very healthy population. So I think it answered an important question for a narrow population of patients," she added, but how the findings should apply to older patients is still unclear.
In his remarks as invited discussant, Robert O. Bonow, MD, Northwestern University Feinberg School of Medicine in Chicago, Illinois, also touched on the generalizability of the results, particularly with respect to those patients in the TAVR trials.
"So the question would be, would these excellent results obtained in this single trial be transportable to the United States in large centers where sometimes the operative mortality is not zero and we do indeed have the risks of stroke as we follow our patients?" Bonow said.
Current AHA/ACC guidelines give a class IIa recommendation to aortic valve replacement for very severe aortic stenosis with a Vmax>5.5 m/sec, he noted.
"Does the current data move the playing field? Does it move the ball? Should we be talking about moving our threshold down to 4.5, or maybe increasing the class IIa [indications] up to class I?" he asked.
"I think we need to wait to see more data to support these excellent results from Dr Kang, but in the meantime, for those of us who see patients, one could argue again that the majority of these patients do come to a surgical endpoint within a very short period of time, so from a clinical management point of view, I think we see already the data suggesting we could move the ball forward, and now we have these excellent outcome data from Korea as well," Bonow said.
Similar points are made in an accompanying NEJM editorial by Patrizio Lancellotti, MD, PhD, University of Lige Hospital, Interdisciplinary Cluster for Applied Genoproteomics Cardiovascular Sciences, Centre Hospitalier Universitaire Sart-Tilman, Belgium, and Mani A. Vannan, MB, BS, Piedmont Heart Institute, Marcus Heart Valve Center, Atlanta, Georgia. They also point out that the population was younger, with fewer comorbidities and more bicuspid valves than was seen in current TAVR trials, and note that many of the patients in the trial would have met current IIa criteria for intervention.
"So although the trial by Kang et al has certainly emphasized the challenge of ascertaining valve-related symptoms in the real world, direct extension of these results to patients with asymptomatic severe aortic stenosis cannot be made at this time," Lancellotti and Vannan write.
They suggest waiting on results of ongoing trials of early TAVR in patients with asymptomatic severe aortic stenosis "for further guidance." Those trials include Aortic Valve Replacement versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis (AVATAR), Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients with Severe AS (EVOLVED), Early Surgery for Patients with Asymptomatic Aortic Stenosis (ESTIMATE), and Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis (EARLY TAVR).
The study was funded by the Korean Institute of Medicine. Kang reports receiving grants from the Korean Institute of Medicine during the conduct of the study. Lancellotti has disclosed no relevant financial relationships. Vannan reports reciving grants and nonfinancial support from Siemens and grants from Abbott, Medtronic, and Lantheus outside the submitted work. Bonow reports no relevant financial relationships.
N Engl J Med. Published online November 16, 2019. Abstract, Editorial
American Heart Association (AHA) Scientific Sessions 2019: Presented November 16, 2019.
Follow Susan Jeffrey on Twitter: @sgjeffrey. For more from theheart.org | Medscape Cardiology, follow us on Twitter and Facebook.
.
Read the original post:
RECOVERY: Early Surgery Best in Severe Asymptomatic AS? - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]